
One component of project expansion will determine if suboptimal antibody responses in long COVID blood contribute to spike protein persistence, microclot formation, and other parameters being measured by the Harvard team.
For the second consecutive year, funding will expand a Harvard Medical School-based project documenting immune, coagulation, and blood vessel abnormalities in both adult and pediatric long COVID patients
(Medford MA, November 15, 2024) – PolyBio Research Foundation is grateful to announce a new grant from the Wallace Research Foundation – a non-profit dedicated to supporting medical research, education, and the environment. The grant builds on a previous Wallace Research Foundation donation, allowing for further expansion the multi-laboratory project “Delineation of coagulation, innate immune, and vascular blood-based biomarkers in long COVID.” Extended funding will allow the project team based at Harvard Medical School to add targeted analysis for SARS-CoV-2 proteins and other metrics into the study. It will also enable a new collaboration with the J. Craig Venter Institute to determine if suboptimal or dysregulated antibody responses underly components of immune or coagulation dysfunction already being documented by the Harvard team.
Specifically, the grant will take advantage of the PolyBio LongCovid Research Consortium collaborative network to send participant blood samples to two new expert collaborators: Dr. David Walt at Harvard Medical School and Dr. Gene Tan at the J. Craig Venter Institute. They will use advanced assays to measure SARS-CoV-2 proteins and suboptimal/dysfunctional antibody responses in samples. Past and present infectious history will also be characterized to further understand how previous viral or bacterial infections may impact the immune response to subsequent challenge. These analyses will be performed on blood samples collected from adult patients with long COVID, but also children with the condition. In addition, funding for at-home phlebotomy allows a nurse phlebotomist to visit the homes of Boston-area homebound long COVID patients, allowing underserved severe patients to also participate in the research.

The project will now perform ultrasensitive testing for SARS-CoV-2 proteins on long COVID blood samples. The same method (performed by David Walt’s lab) was also used in this recent paper that found increased levels of viral proteins in participants with long COVID symptoms.
The Harvard Medical School team that forms the main site of the study pulls together the expertise of top researchers working on complimentary aspects of long COVID biology. Neuroscientist Dr. Michael VanElzakker oversees adult patient recruitment and sample collection and analysis. Pediatric pulmonologist Dr. Lael Yonker leads the pediatric long COVID arm of the study. Dr. Daniel Irimia, an internationally recognized expert in bioengineered microsystems and related tools, is spearheading the development of microfluidic devices that are allowing certain project biomarkers to be more precisely quantified. PolyBio’s President and Research Director Dr. Amy Proal helps to oversee the work, ensuring that findings are communicated to other Long Covid Research Consortium teams.
“We are incredibly grateful for the new grant” says Dr. Proal. “The project pulls together the brain power of researchers using unique and advanced technologies. By applying these methods to blood collected from the same patients, the team’s ability to identify interrelated long COVID biomarkers is greatly amplified.”
